The METEOR study reveals distinct clinical features in spondyloarthritis (SpA) patients with vs. without IBD. Key features of those with IBD: - Lower male prevalence - Higher uveitis rates - Lower psoriasis rates - More structural damage in SI joints Mirroring gut… https://t.co/EyBZQ91DDn

• https://x.com/i/web/status/1857815895503982995

🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

• https://x.com/i/web/status/1857812119649136924
• https://x.com/AdelaCastro222/status/1857812119649136924/photo/1
• https://x.com/AdelaCastro222/status/1857812119649136924/photo/1

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

• https://x.com/AdelaCastro222/status/1857810860795638038/photo/1

Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

• https://x.com/AkhilSoodMD/status/1857810357684941164/photo/1

High PBO effect in PsA studies Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12: 💡PBO rates significantly increased over time. 💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe

• https://x.com/i/web/status/1857807792729416051

#0582🔬Challenges in Achieving PsA Disease Control ➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively 🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes. 🩺Unmet needs remain in PsA; tailored Rx needed #ACR24 @RheumNow

The rising placebo response rates in PsA trials are linked to global recruiting patterns, with more studies in less affluent countries. Limited access to healthcare may drive this trend, highlighting the need for awareness among stakeholders. Plenary Abstr#0722… https://t.co/FplpSlIamR https://t.co/NIp76IS6TZ

• https://x.com/i/web/status/1857805827815752105
• https://x.com/synovialjoints/status/1857805827815752105/photo/1

Kerschbaumer et al. Rising placebo rates in PsA RCTs appear linked to changes in global recruitment patterns. Dramatic relationship between GNI and placebo response rate. Crucial information for properly planning future trials @RheumNow #ACR24 Abstr#0772 https://t.co/PtHs2RXe0f https://t.co/OKG6czQrYD

• Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinic…
• https://x.com/RichardPAConway/status/1857804569620754475/photo/1

Location of research matters Ab#0772 Global recruiting patterns impact PBO in PsA PBO results improve w time - 0.9%/year More globalization of trials w time Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response @RheumNow #ACR24